Renal System, Endocrinology
16. Oct 2018
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition
KEY POINTS:
Increased activation of the renin-angiotensin-aldosterone system (RAAS) and elevated growth factor production are of crucial importance in the development of renal fibrosis leading to diabetic kidney disease. The aim of this study was to provide evidence for the antifibrotic potential o…
Read the publication
Journal:
Authors:
- koszegi S,
- Molnar A,
- Lenart L,
- Hodrea J,
- Balogh DB,
- Lakat T,
- Szkibinszjik J,
- Hoszu A,
- Sparding N,
- Fenovese F,
- Wagner L,
- Vannay A,
- Szabo AJ,
- Fekete A,
Obesity
14. Mar 2017
Optimization of Tolerability and Efficacy of Dual Amylin and Calcitonin Receptor Agonist, KBP-089, through Dose Escalation and Combination with a GLP-1 Analogue
Amylin and GLP-1 agonism induce a well-known anorexic effect at dose initiation, which is managed by dose escalation. In this study, we investigated how to optimize tolerability, while maintaining efficacy of KBP-089. Furthermore, we tested the GLP-1 add-on potential of KBP-089 in HFD rats. KBP-089 …
Read the publication
Journal:
Authors:
- Gydesen S,
- Andreassen KV,
- Hjuler ST,
- Hellgren LI,
- Karsdal MA,
- Henriksen K,
Endocrinology, Type 2-Diabetes
1. May 2016
KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight
This study aims to elucidate the mechanism behind the potent weight loss induced by dual amylin and calcitonin receptor agonists (DACRA) through comparison of the novel DACRA KBP-088 with the amylinomimetic davalintide with regard to in vitro receptor pharmacology and in vivo efficacy on food intake…
Read the publication
Journal:
Authors:
- Gydesen S,
- Hjuler ST,
- Christensen JM,
- Karsdal MA,
- Arbit E,
- Andreassen KV,
Endocrinology, Type 2-Diabetes
31. Jul 2014
A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats
The present study investigated a novel oral dual amylin and calcitonin receptor agonist (DACRA), KBP-042, in head-to-head comparison with salmon calcitonin (sCT) with regard to in vitro receptor pharmacology, ex vivo pancreatic islet studies, and in vivo proof of concept studies in diet-induced obes…
Read the publication
Journal:
Authors:
- Andreassen KV,
- Feigh M,
- Hjuler ST,
- Gydesen S,
- Henriksen JE,
- Beck-Nielsen H,
- Christiansen C,
- Karsdal MA,
- Henriksen K,
Type 2-Diabetes, Obesity, Endocrinology
6. May 2014
A Novel Oral Dual Amylin and Calcitonin Receptor Agonist (KBP-042) Exerts Anti-Obesity and Anti-Diabetic Effects in Rats
The present study investigated a novel oral dual amylin and calcitonin receptor agonist (DACRA), KBP-042, in head-to-head comparison with salmon calcitonin (sCT) with regard to in vitro receptor pharmacology, ex vivo pancreatic islet studies, and in vivo proof of concept studies in diet-induced obes…
Read the publication
Journal:
Authors:
- Andreassen KV,
- Feigh M,
- Hjuler ST,
- Gydesen S,
- Henriksen JE,
- Beck-Nielsen H,
- Christiansen C,
- Karsdal MA,
- Henriksen K,